The 2017 meeting of the American Academy of Neurology (AAN) took place in Boston from 22 to 28 April.
The following is a selection of the news coverage of information presented at the meeting. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for our free Open Door newsletter or our regular email alerts.
Results from MS-MRIUS (Multiple sclerosis and clinical outcome and MRI in the US) study of Gilenya (fingolimod) in a real world setting found three out of five participants achieved NEDA-3 (no relapses, no new lesions no disability progression) and a third achieved NEDA-4 (those three measures plus reduced brain tissue loss).
MS Trust link: Gilenya (fingolimod)
Lemtrada long-term data
Six year follow up studies found that two out of three people who hadn't previously used a disease modifying drug (DMD) only required a two year course of Lemtrada (alemtuzumab). In a trial where people had previously had unsuccessful DMD treatment, half only needed the two year course. In year 6, almost three quarters were free of disability worsening and 43% of these showed an improvement lasting six months.
Source: Medpage Today
MS Trust link: Lemtrada (alemtuzumab)
A trial compared myelin repair in people with relapsing or secondary progressive MS taking either opicinumab (anti-LINGO-1) or Avonex (beta interferon 1a). Although the trial was negative and showed no significant difference, researchers identified younger people with relapsing MS and short disease duration as better responders and plan to focus further research on them
Source: MS News Today
MS Trust link: Opicinumab (anti-LINGO-1)
Importance of early effective treatment
Real-world data for Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) suggest that treatment at early disease stages improves outcomes and prevents disability development
Measuring disease activity in progressive MS
Researchers suggest a way to expand the idea of NEDA to make it more relevant as a marker for people with progressive MS. As well as no relapses, no new lesions and no increase in EDSS, NEPAD adds in increase of 20% of more in 9-hole peg test and 25-foot walk. Ocrelizumab did well on this new measure vs placebo (29.9% v 9.4%)
Source: MedPage Today
MS Trust link: Progressive MS
Predicting risk of conversion to SPMS
A study recruited people who had had relapsing remitting MS for at least 15 years. When they were reviewed five years later, those who reported fatigue and lower limb problems at the start of the trial were more likely to have developed secondary progressive MS
Source: Neurology Advisor
MS Trust link: Secondary progressive MS